Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neurol
    April 2024
  1. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
    Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
    >> Share

  2. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
    Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
    >> Share

  3. SINGER BA, Feng J, Chiong-Rivero H
    Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
    >> Share

  4. ZHANG Y, Liu D, Zhang Z, Huang X, et al
    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
    J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
    >> Share

  5. STALTER J, Pars K, Witt K
    Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
    J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
    >> Share

  6. MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
    Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
    >> Share

  7. CELIK M, Baba C, Irmak C, Ozakbas S, et al
    Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
    >> Share

  8. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
    Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
    >> Share

  9. TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
    Takotsubo cardiomyopathy in Guillain-Barre syndrome.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
    >> Share

  10. MAIDA E, Moccia M, Palladino R, Borriello G, et al
    ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
    >> Share

  11. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
    Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
    >> Share

  12. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
    Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
    >> Share

  13. MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
    Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
    J Neurol. 2024;271:1707-1716.
    >> Share

  14. WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
    Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
    J Neurol. 2024;271:1861-1872.
    >> Share

  15. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    >> Share

  16. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    >> Share

  17. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    >> Share

    March 2024
  18. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    >> Share

  19. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    >> Share

  20. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    >> Share

  21. ZHANG H, Ma J, Feng Y, Ma H, et al
    Efgartigimod in the treatment of Guillain-Barre syndrome.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
    >> Share

  22. FUCHS L, Shelly S, Vigiser I, Kolb H, et al
    Real-World experience with efgartigimod in patients with myasthenia gravis.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
    >> Share

  23. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    >> Share

  24. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
    >> Share

  25. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    >> Share

  26. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    >> Share

  27. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    >> Share

  28. VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
    Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
    >> Share

  29. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    >> Share

  30. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    >> Share

  31. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    >> Share

  32. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    >> Share

  33. LI J, Wu X, Chu T, Tan X, et al
    The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
    >> Share

  34. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    >> Share

    February 2024
  35. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    >> Share

  36. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    >> Share

  37. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    >> Share

  38. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    >> Share

  39. NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
    Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
    J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
    >> Share

  40. WEISS MD, Freimer M, Leite MI, Maniaol A, et al
    Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
    J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
    >> Share

  41. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
    J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
    >> Share

  42. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
    Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
    >> Share

  43. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    >> Share

  44. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    >> Share

  45. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share

  46. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
    Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
    J Neurol. 2024;271:1019-1022.
    >> Share

    January 2024
  47. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  48. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  49. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  50. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
    Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
    >> Share

  51. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    >> Share

  52. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    >> Share

  53. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    >> Share

  54. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    >> Share

  55. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    >> Share

  56. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
    Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    J Neurol. 2024;271:75-78.
    >> Share

  57. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
    Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
    J Neurol. 2024;271:564-574.
    >> Share

  58. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
    Neurological manifestation of HEV infection: still a rare disease entity?
    J Neurol. 2024;271:386-394.
    >> Share

  59. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    >> Share

  60. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
    Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    J Neurol. 2024;271:141-176.
    >> Share

    December 2023
  61. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    >> Share

  62. LIU M, Ren H, Wang L, Fan S, et al
    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
    J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
    >> Share

  63. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    >> Share

  64. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    >> Share

  65. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    >> Share

  66. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    >> Share

  67. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    >> Share

  68. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    >> Share

  69. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    >> Share

  70. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    >> Share

    November 2023
  71. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    >> Share

  72. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    >> Share

  73. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    >> Share

  74. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  75. SUN Y, Li G, Liu X, Zhao X, et al
    Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
    >> Share

  76. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    >> Share

  77. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    >> Share

  78. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    >> Share

  79. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    >> Share

    October 2023
  80. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    >> Share

  81. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    >> Share

  82. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    >> Share

  83. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share

  84. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    >> Share

  85. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    >> Share

  86. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    >> Share

  87. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    >> Share

  88. MANZANO GS, McEntire C, Venna N
    Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
    >> Share

  89. ZHANG Z, Wang Z, Du X, Huang X, et al
    Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
    J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
    >> Share

  90. KRAKER JA, Chen JJ
    An update on optic neuritis.
    J Neurol. 2023;270:5113-5126.
    >> Share

  91. BRISCA G, Marini C, Buratti S, Mariani M, et al
    Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
    J Neurol. 2023;270:5034-5047.
    >> Share

  92. WANG R, Sun D, Du Q, Shi Z, et al
    Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
    J Neurol. 2023;270:5085-5089.
    >> Share

    September 2023
  93. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    >> Share

  94. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    >> Share

  95. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
    Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
    J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
    >> Share

  96. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    >> Share

  97. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    >> Share

  98. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
    J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
    >> Share

  99. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    >> Share

  100. DI STEFANO V, Alonge P, Rini N, Militello M, et al
    Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
    >> Share

  101. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    >> Share

  102. MCCOMBE JA, Klassen BT, Flanagan EP, Teener JW, et al
    Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome.
    J Neurol. 2023;270:4555-4557.
    >> Share

  103. NAKAMURA N, Ishikawa H, Matsuyama H, Shindo A, et al
    Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation.
    J Neurol. 2023;270:4529-4532.
    >> Share

    August 2023
  104. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
    Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
    J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
    >> Share

  105. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    >> Share

  106. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
    A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
    >> Share

  107. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    >> Share

  108. KUDO A, Yaguchi H, Tanaka K, Kimura A, et al
    A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
    J Neurol. 2023 Aug 23. doi: 10.1007/s00415-023-11946.
    >> Share

  109. GOERTZEN A, Altawashi AK, Rieck J, Veh RW, et al
    Autoimmune processes in neurological patients are much more common than presently suspected.
    J Neurol. 2023 Aug 21. doi: 10.1007/s00415-023-11901.
    >> Share

  110. CHANSON JB, Bouhour F, Aube-Nathier AC, Mallaret M, et al
    Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11925.
    >> Share

  111. SPIERER R, Lavi I, Bloch S, Mazar M, et al
    Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
    >> Share

  112. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
    Multiple sclerosis lesions that impair memory map to a connected memory circuit.
    J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
    >> Share

  113. AL-ANI A, Chen JJ, Costello F
    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
    J Neurol. 2023;270:4132-4150.
    >> Share

    July 2023
  114. MAHMOOD A, Hawken J, Robertson NP
    Clinical trials in myasthenia gravis.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11903.
    >> Share

  115. QIN M, Chen J, Guo X, Xiang X, et al
    Movement disorders in autoimmune encephalitis: an update.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11881.
    >> Share

  116. ROEBEN B, Scharf M, Miske R, Teegen B, et al
    Seroprevalence of autoimmune antibodies in degenerative ataxias: a broad, disease-controlled screening in 456 subjects.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11900.
    >> Share

  117. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
    >> Share

  118. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
    Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
    J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
    >> Share

  119. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
    Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
    >> Share

  120. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
    Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
    J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
    >> Share

  121. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    >> Share

  122. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
    Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
    J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
    >> Share

  123. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
    Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
    >> Share

  124. MOOG TM, Smith AD, Burgess KW, McCreary M, et al
    High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:3595-3602.
    >> Share

  125. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    J Neurol. 2023;270:3341-3368.
    >> Share

  126. LUMSDEN DE, Lim M, Irani S
    Letter to the editors: comment on "Status dystonicus in adult patients with anti-N-methyl-D-asparate-acid receptor encephalitis".
    J Neurol. 2023;270:3630-3631.
    >> Share

  127. TEZUKA T, Okuzumi S, Nakashima C, Ide T, et al
    Dysautonomia associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:3413-3423.
    >> Share

    June 2023
  128. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
    The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
    >> Share

  129. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
    >> Share

  130. LIANG Y, Wang G, Li B, Li G, et al
    Autoimmune glial fibrillary acidic protein astrocytosis mimicking tuberculous meningitis: a retrospective study.
    J Neurol. 2023 Jun 20. doi: 10.1007/s00415-023-11818.
    >> Share

  131. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
    Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
    >> Share

  132. KRIEF N, Gabriel R, Cauquil C, Adams D, et al
    Clinical features and maternal and fetal outcomes in women with Guillain-Barre syndrome in pregnancy.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11808.
    >> Share

  133. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
    The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
    >> Share

  134. CHOMPOOPONG P, Rezk M, Mirman I, Berini SE, et al
    TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11798.
    >> Share

  135. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
    >> Share

  136. HTET ZM, Tallantyre E
    Optic neuritis and MOGAD.
    J Neurol. 2023;270:3278-3279.
    >> Share

  137. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    >> Share

  138. YIN Z, Qiu Y, Duan A, Fang T, et al
    Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    J Neurol. 2023;270:2950-2963.
    >> Share

  139. ROSSI S, Gelsomino F, Rinaldi R, Muccioli L, et al
    Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:2975-2986.
    >> Share

    May 2023
  140. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
    >> Share

  141. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    >> Share

  142. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    >> Share

  143. LIU B, Hu J, Sun C, Qiao K, et al
    Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11759.
    >> Share

  144. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    >> Share

  145. ZHANG Y, Cui L, Chen W, Huang H, et al
    Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.
    J Neurol. 2023;270:2693-2701.
    >> Share

  146. DENG Z, Wang H, Huang K, Li Y, et al
    Association between vascular risk factors and idiopathic normal pressure hydrocephalus: a Mendelian randomization study.
    J Neurol. 2023;270:2724-2733.
    >> Share

    April 2023
  147. VARLEY JA, Strippel C, Handel A, Irani SR, et al
    Autoimmune encephalitis: recent clinical and biological advances.
    J Neurol. 2023 Apr 28. doi: 10.1007/s00415-023-11685.
    >> Share

  148. VOGRIG A, Versace S, Gigli GL, Fabris M, et al
    Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination.
    J Neurol. 2023 Apr 28:1-5. doi: 10.1007/s00415-023-11723.
    >> Share

  149. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    >> Share

  150. MEISEL A, Annane D, Vu T, Mantegazza R, et al
    Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11699.
    >> Share

  151. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    >> Share

  152. GILHUS NE
    Myasthenia gravis, respiratory function, and respiratory tract disease.
    J Neurol. 2023 Apr 26:1-12. doi: 10.1007/s00415-023-11733.
    >> Share

  153. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    >> Share

  154. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    >> Share

  155. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    >> Share

  156. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
    Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
    J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
    >> Share

  157. GADOTH A, Devine MF, Pittock SJ, McKeon A, et al
    Sleep disturbances associated with DPPX autoantibodies: a case series.
    J Neurol. 2023 Apr 7. doi: 10.1007/s00415-023-11698.
    >> Share

  158. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
    >> Share

  159. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
    >> Share

  160. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
    Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
    J Neurol. 2023;270:2271-2282.
    >> Share

  161. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
    PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    J Neurol. 2023;270:2329-2332.
    >> Share

  162. GHOLIZADEH S, Exuzides A, Lewis KE, Palmer C, et al
    Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.
    J Neurol. 2023;270:2048-2058.
    >> Share

  163. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
    CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
    J Neurol. 2023;270:2042-2047.
    >> Share

  164. HIEKE A, Spenner M, Schmitz F, Schumacher A, et al
    The impact of the SARS-CoV-2-pandemic on patients with chronic inflammatory neuropathies: results from the German INHIBIT register.
    J Neurol. 2023;270:1815-1822.
    >> Share

  165. NEHME A, Lanthier S, Boulanger M, Aouba A, et al
    Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices.
    J Neurol. 2023;270:1989-1998.
    >> Share

    March 2023
  166. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
    >> Share

  167. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
    >> Share

  168. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
    Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
    J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
    >> Share

  169. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
    >> Share

  170. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
    Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
    J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
    >> Share

  171. VU T, Ortiz S, Katsuno M, Annane D, et al
    Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
    J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11617.
    >> Share

  172. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
    Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
    J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
    >> Share

  173. LI G, You Q, Hou X, Zhang S, et al
    The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
    >> Share

  174. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
    >> Share

  175. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
    In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
    >> Share

  176. TAKAI K, Endo T, Seki T, Inoue T, et al
    Congestive myelopathy due to craniocervical junction arteriovenous fistulas mimicking transverse myelitis: a multicenter study on 27 cases.
    J Neurol. 2023;270:1745-1753.
    >> Share

  177. VABANESI M, Pinto AL, Vogrig A, Goncalves D, et al
    SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.
    J Neurol. 2023;270:1691-1701.
    >> Share

  178. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
    Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    J Neurol. 2023;270:1416-1429.
    >> Share

  179. NGUYEN TT, Kang JJ, Chae JH, Lee E, et al
    Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11611.
    >> Share

  180. SCHEGK E, Beiser I, Achtnichts L, Nedeltchev K, et al
    Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11632.
    >> Share

    February 2023
  181. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
    Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
    J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
    >> Share

  182. MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
    Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
    J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
    >> Share

  183. DIXON L, Colquhoun M, Taylor E, Carlucci F, et al
    Orbital giant cell arteritis: two cases of bilateral orbital inflammation and arterial diffusion restriction on MRI.
    J Neurol. 2023 Feb 11. doi: 10.1007/s00415-023-11593.
    >> Share

  184. SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
    Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
    J Neurol. 2023;270:1178-1186.
    >> Share

  185. HUANG L, Wang Y, Zhang R
    Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    J Neurol. 2023;270:759-768.
    >> Share

  186. FIONDA L, Lauletta A, Leonardi L, Perez JA, et al
    Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.
    J Neurol. 2023;270:960-974.
    >> Share

  187. GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
    Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
    J Neurol. 2023;270:1135-1140.
    >> Share

  188. MAGRO G, Barone S, Tosto F, De Martino A, et al
    Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
    J Neurol. 2023;270:595-600.
    >> Share

    January 2023
  189. MINAMINO M, Miyamoto K, Kuwahara M, Yoshikawa K, et al
    Characteristics of Guillain-Barre syndrome in super-elderly individuals.
    J Neurol. 2023 Jan 16. doi: 10.1007/s00415-023-11567.
    >> Share

  190. CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
    Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
    J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
    >> Share

  191. SACCA F, Barnett C, Vu T, Peric S, et al
    Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    J Neurol. 2023 Jan 4. doi: 10.1007/s00415-022-11517.
    >> Share

  192. LEE SU, Baek SH, Kim HJ, Choi JY, et al
    Acute comitant strabismus in anti-GQ1b antibody syndrome.
    J Neurol. 2023;270:486-492.
    >> Share

  193. HAGEBOUTROS K, Hattiangadi Thomas N, Hutchinson M, Banwell B, et al
    Neuropsychological functioning in children and adolescents with anti-NMDA receptor encephalitis (anti-NMDARE).
    J Neurol. 2023;270:402-412.
    >> Share

  194. YANG S, Zhang C, Zhang TX, Feng B, et al
    A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:348-356.
    >> Share

  195. DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
    Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
    J Neurol. 2023;270:240-249.
    >> Share

    December 2022
  196. BARBAGALLO M, Straumann D, Binaghi E, Schmick A, et al
    A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection.
    J Neurol. 2022 Dec 28:1-5. doi: 10.1007/s00415-022-11548.
    >> Share

  197. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
    >> Share

  198. TIERNEY P, Zekeridou A, Adam O
    Phosphodiesterase 10A autoimmunity presenting as cerebellar ataxia responsive to plasma exchange: a case report.
    J Neurol. 2022 Dec 26. doi: 10.1007/s00415-022-11542.
    >> Share

  199. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
    Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
    >> Share

  200. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
    Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
    >> Share

  201. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
    The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
    J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
    >> Share

  202. GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
    Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
    J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
    >> Share

  203. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
    Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    J Neurol. 2022;269:6504-6511.
    >> Share

  204. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
    J Neurol. 2022;269:6366-6376.
    >> Share

    November 2022
  205. SIMPSON R, Posa S, Bruno T, Simpson S, et al
    Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
    J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
    >> Share

  206. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
    Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
    J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
    >> Share

  207. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
    Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
    J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
    >> Share

  208. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
    Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
    >> Share

  209. KWON YN, Woodhall M, Sung JJ, Kim KK, et al
    Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11458.
    >> Share

  210. KIM S, Kim KH, Chung HY, Park HJ, et al
    Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.
    J Neurol. 2022 Nov 16. pii: 10.1007/s00415-022-11485.
    >> Share

  211. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
    >> Share

  212. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
    Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
    J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
    >> Share

  213. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
    >> Share

  214. SIMPSON R, Posa S, Langer L, Bruno T, et al
    A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
    >> Share

  215. TERESHKO Y, Gigli GL, Pez S, De Pellegrin A, et al
    New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11472.
    >> Share

  216. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
    Health-related quality of life in Japanese patients with multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
    >> Share

  217. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
    Vitamin D genetic risk scores in multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
    >> Share

  218. JARIUS S, Haas J, Wildemann B
    Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis.
    J Neurol. 2022 Nov 4. pii: 10.1007/s00415-022-11417.
    >> Share

  219. STRANO CMM, Sorrenti B, Bosco L, Falzone YM, et al
    Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
    J Neurol. 2022;269:6152-6154.
    >> Share

    October 2022
  220. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
    Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
    J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
    >> Share

  221. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
    Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
    J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
    >> Share

  222. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
    NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
    >> Share

  223. COSTELLO F, Burton JM
    Contemporary management challenges in seropositive NMOSD.
    J Neurol. 2022;269:5674-5681.
    >> Share

  224. KANG L, Wan C
    Paraneoplastic syndrome in neuroophthalmology.
    J Neurol. 2022;269:5272-5282.
    >> Share

  225. LEVI-STRAUSS J, Provost C, Wane N, Jacquemont T, et al
    NMOSD typical brain lesions after COVID-19 mRNA vaccination.
    J Neurol. 2022;269:5213-5215.
    >> Share

  226. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    J Neurol. 2022;269:5319-5327.
    >> Share

    September 2022
  227. ZHANG S, Yang S, Lu J, Liu S, et al
    CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review.
    J Neurol. 2022 Sep 30. pii: 10.1007/s00415-022-11369.
    >> Share

  228. STASCHEIT F, Grittner U, Hoffmann S, Mergenthaler P, et al
    Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
    J Neurol. 2022 Sep 27. pii: 10.1007/s00415-022-11389.
    >> Share

  229. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
    In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
    >> Share

  230. PAGANI E, Storelli L, Pantano P, Petsas N, et al
    Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
    >> Share

  231. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    >> Share

  232. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    >> Share

  233. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    >> Share

  234. REYES-VEGA MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, et al
    Clinical features of Guillain-Barre syndrome and factors associated with mortality during the 2019 outbreak in Peru.
    J Neurol. 2022 Sep 13. pii: 10.1007/s00415-022-11331.
    >> Share

  235. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
    Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
    J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
    >> Share

  236. MAIER A, Kapfenberger R, Katona I, Weis J, et al
    Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.
    J Neurol. 2022 Sep 9. pii: 10.1007/s00415-022-11340.
    >> Share

  237. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    >> Share

    August 2022
  238. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    >> Share

  239. GUEGUEN A, Hijazi B, Zuber K, Deschamps R, et al
    Generalization of ocular myasthenia gravis 10 years after onset.
    J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11316.
    >> Share

  240. BARNAY M, Duval F, Sole G, Carla L, et al
    Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
    J Neurol. 2022 Aug 22. pii: 10.1007/s00415-022-11345.
    >> Share

  241. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Correction to: Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11290.
    >> Share

  242. JAFARPOUR S, Banerjee A, Boyd NK, Vogel BN, et al
    Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11325.
    >> Share

  243. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
    J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
    >> Share

  244. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
    >> Share

    July 2022
  245. DORON A, Piura Y, Vigiser I, Kolb H, et al
    BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    J Neurol. 2022 Jul 30. pii: 10.1007/s00415-022-11303.
    >> Share

  246. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
    Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
    >> Share

  247. BLACKMAN G, Lim MF, Pollak T, Al-Diwani A, et al
    The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11224.
    >> Share

  248. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
    SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
    >> Share

  249. TAN X, Liu Y, Wu X, Guo Y, et al
    Guillain-Barre-like syndrome: an uncommon feature of CASPR2 and LGI1 autoimmunity.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11248.
    >> Share

  250. EID K, Torkildsen O, Aarseth J, Celius EG, et al
    Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
    >> Share

  251. MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
    Seronegative myasthenic crisis: a multicenter analysis.
    J Neurol. 2022;269:3904-3911.
    >> Share

  252. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    >> Share

    June 2022
  253. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    >> Share

  254. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    >> Share

  255. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    >> Share

  256. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    >> Share

  257. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    >> Share

  258. ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
    Neuroimmune disorders in COVID-19.
    J Neurol. 2022;269:2827-2839.
    >> Share

  259. YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
    Bedside and laboratory diagnostic testing in myasthenia.
    J Neurol. 2022;269:3372-3384.
    >> Share

  260. LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
    Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
    J Neurol. 2022;269:3359-3362.
    >> Share

  261. JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
    Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
    J Neurol. 2022;269:2850-2853.
    >> Share

  262. AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
    Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
    J Neurol. 2022;269:3175-3179.
    >> Share

  263. VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
    MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
    J Neurol. 2022;269:3159-3166.
    >> Share

  264. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    >> Share

  265. AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
    Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2022;269:3136-3146.
    >> Share

  266. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    >> Share

  267. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    >> Share

    May 2022
  268. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
    >> Share

  269. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    >> Share

  270. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    >> Share

  271. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
    >> Share

  272. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    >> Share

  273. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    >> Share

  274. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    >> Share

  275. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    >> Share

  276. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    >> Share

  277. GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
    Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
    >> Share

  278. SANSONE G, Bonifati DM
    Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
    >> Share

  279. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    >> Share

  280. GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
    Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
    J Neurol. 2022;269:2293-2300.
    >> Share

  281. WEISS D, Cantre D, Zettl UK, Storch A, et al
    Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
    J Neurol. 2022;269:2778-2780.
    >> Share

  282. HIROSE S, Hara M, Kamei S, Dalmau J, et al
    Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:2486-2492.
    >> Share

    April 2022
  283. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    >> Share

  284. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    >> Share

  285. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    >> Share

  286. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    >> Share

  287. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    >> Share

  288. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    >> Share

  289. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    >> Share

  290. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    >> Share

  291. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
    >> Share

  292. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    >> Share

  293. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    >> Share

  294. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    >> Share

  295. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    >> Share

  296. MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
    Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    J Neurol. 2022;269:1996-2003.
    >> Share

    March 2022
  297. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
    >> Share

  298. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
    >> Share

  299. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    >> Share

  300. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
    >> Share

  301. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    >> Share

  302. DU Y, Li C, Hao YF, Zhao C, et al
    Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
    >> Share

  303. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    >> Share

  304. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    >> Share

  305. KUBICKI K, Grzybowski A
    Pioneers in neurology: Charles Miller Fisher (1913-2012).
    J Neurol. 2022;269:1727-1729.
    >> Share

  306. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.
    >> Share

  307. KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
    Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
    J Neurol. 2022;269:1121-1132.
    >> Share

  308. WANG Y, Wang Y, Huo L, Li Q, et al
    SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
    J Neurol. 2022;269:1071-1092.
    >> Share

  309. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    >> Share

  310. XIE H, Shao Y, Du J, Song Y, et al
    Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2022;269:1641-1650.
    >> Share

  311. NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
    NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
    J Neurol. 2022;269:1618-1630.
    >> Share

  312. CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
    Application of deep-learning to the seronegative side of the NMO spectrum.
    J Neurol. 2022;269:1546-1556.
    >> Share

  313. HU J, Sun C, Lu J, Zhao C, et al
    Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    J Neurol. 2022;269:1250-1263.
    >> Share

  314. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    >> Share

    February 2022
  315. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
    >> Share

  316. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    >> Share

  317. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    >> Share

  318. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    >> Share

  319. SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
    Neurologic manifestations of giant cell arteritis.
    J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
    >> Share

  320. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    >> Share

  321. ISMAIL II, Salama S
    Association of CNS demyelination and COVID-19 infection: an updated systematic review.
    J Neurol. 2022;269:541-576.
    >> Share

  322. PATZIG M, Forbrig R, Kupper C, Eren O, et al
    Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
    J Neurol. 2022;269:982-996.
    >> Share

  323. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    >> Share

  324. SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
    Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
    J Neurol. 2022;269:907-912.
    >> Share

  325. BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
    J Neurol. 2022;269:945-955.
    >> Share

  326. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    >> Share

    January 2022
  327. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    >> Share

  328. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    >> Share

  329. GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
    The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
    J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
    >> Share

  330. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    >> Share

  331. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
    >> Share

  332. MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
    Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
    >> Share

  333. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    >> Share

  334. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    >> Share

  335. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    >> Share

  336. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    >> Share

  337. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    >> Share

  338. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
    >> Share

  339. TALAEI M, Robertson NP
    Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
    J Neurol. 2022;269:534-536.
    >> Share

  340. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    >> Share

  341. XU J, Guo Y, Li J, Lv X, et al
    Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:389-398.
    >> Share

  342. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.
    >> Share

  343. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    >> Share

    December 2021
  344. LEGUY S, Le Page E, Drapier S
    Elderly onset neuromyelitis optica spectrum disorder: a case report.
    J Neurol. 2021;268:4897-4898.
    >> Share

  345. SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
    COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
    J Neurol. 2021;268:4448-4478.
    >> Share

  346. KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
    MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
    J Neurol. 2021;268:4824-4833.
    >> Share

  347. FLANAGAN EP
    Paraneoplastic disorders of the nervous system.
    J Neurol. 2021;268:4899-4907.
    >> Share

  348. CABAL-HERRERA AM, Mateen FJ
    COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
    J Neurol. 2021;268:4479-4482.
    >> Share

  349. SIRITHO S, Nopsopon T, Pongpirul K
    Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
    J Neurol. 2021;268:4549-4562.
    >> Share

  350. HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
    Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    J Neurol. 2021;268:4522-4536.
    >> Share

    November 2021
  351. KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
    When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
    J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
    >> Share

  352. ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
    Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
    >> Share

  353. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
    >> Share

  354. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
    >> Share

  355. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    >> Share

  356. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
    >> Share

  357. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.
    >> Share

  358. MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
    Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
    J Neurol. 2021;268:3995-3997.
    >> Share

    October 2021
  359. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    >> Share

  360. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    >> Share

  361. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    >> Share

  362. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    >> Share

  363. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    >> Share

  364. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    >> Share

  365. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.
    >> Share

  366. FUKAMI Y, Iijima M, Koike H, Yamada S, et al
    Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    J Neurol. 2021;268:3835-3844.
    >> Share

  367. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    >> Share

  368. QUEROL L, Crabtree M, Herepath M, Priedane E, et al
    Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2021;268:3706-3716.
    >> Share

  369. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    >> Share

    September 2021
  370. AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
    Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
    J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.
    >> Share

  371. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    >> Share

  372. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    >> Share

  373. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    >> Share

  374. BERCIANO J
    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
    >> Share

  375. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    >> Share

  376. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    >> Share

  377. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.
    >> Share

    August 2021
  378. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    >> Share

  379. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    >> Share

  380. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    >> Share

  381. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    >> Share

  382. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    >> Share

  383. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    >> Share

  384. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    >> Share

  385. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    >> Share

  386. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.
    >> Share

    July 2021
  387. O SULLIVAN C, Zach F, Moser T, Pilz G, et al
    Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
    J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.
    >> Share

  388. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    >> Share

  389. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    >> Share

  390. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    >> Share

  391. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    >> Share

  392. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    >> Share

    June 2021
  393. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    >> Share

  394. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    >> Share

  395. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    >> Share

  396. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    >> Share

  397. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    >> Share

  398. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    >> Share

  399. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.
    >> Share

  400. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    >> Share

  401. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.
    >> Share

    May 2021
  402. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    >> Share

  403. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    >> Share

  404. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    >> Share

  405. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
    >> Share

  406. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    >> Share

  407. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    >> Share

  408. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    >> Share

  409. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    >> Share

  410. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    >> Share

    April 2021
  411. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    >> Share

  412. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    >> Share

  413. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    >> Share

  414. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    >> Share

  415. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    >> Share

  416. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.
    >> Share

  417. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    >> Share

  418. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    >> Share

  419. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    >> Share

    March 2021
  420. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    >> Share

  421. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    >> Share

    February 2021
  422. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    >> Share

  423. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.
    >> Share

  424. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.
    >> Share

  425. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    >> Share

  426. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    >> Share

    January 2021
  427. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    >> Share

  428. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    >> Share

    July 2020
  429. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    >> Share

  430. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016